Clinical meaning of sarcopenia in patients undergoing endoscopic treatment.
Hiroyuki HisadaYosuke TsujiHikaru KuribaraRyohei MiyataKaori OshioSatoru MizutaniHideki NakagawaRina ChoNobuyuki SakumaYuko MiuraHiroya MizutaniDaisuke OhkiSeiichi YakabiYu TakahashiYoshiki SakaguchiNaomi KakushimaNobutake YamamichiMitsuhiro FujishiroPublished in: Clinical endoscopy (2024)
With increasing global life expectancy, the significance of geriatric assessment parameters has increased. Sarcopenia is a crucial assessment parameter and is defined as the age-related loss of muscle mass and strength. Sarcopenia is widely acknowledged as a risk factor for postoperative complications in diverse advanced malignancies and has a detrimental effect on the long-term prognosis. While most studies have primarily concentrated on the correlation between sarcopenia and advanced cancer, more recent investigations have focused on the relationship between sarcopenia and early-stage cancer. Endoscopic submucosal dissection (ESD), which is less invasive than surgical intervention, is extensively employed in the management of early-stage cancer, although it is associated with complications such as bleeding and perforation. In recent years, several reports have revealed the adverse consequences of sarcopenia in patients with early-stage cancer undergoing ESD. This literature review briefly summarizes the recent studies on the association between sarcopenia and ESD.
Keyphrases
- early stage
- endoscopic submucosal dissection
- skeletal muscle
- papillary thyroid
- community dwelling
- advanced cancer
- patients undergoing
- squamous cell
- palliative care
- randomized controlled trial
- sentinel lymph node
- lymph node metastasis
- squamous cell carcinoma
- radiation therapy
- single cell
- combination therapy
- case control
- neoadjuvant chemotherapy